186 related articles for article (PubMed ID: 1858829)
1. Skeletal integrity in premenopausal and postmenopausal women receiving long-term L-thyroxine therapy.
Greenspan SL; Greenspan FS; Resnick NM; Block JE; Friedlander AL; Genant HK
Am J Med; 1991 Jul; 91(1):5-14. PubMed ID: 1858829
[TBL] [Abstract][Full Text] [Related]
2. Bone mineral density in postmenopausal women treated with L-thyroxine.
Adlin EV; Maurer AH; Marks AD; Channick BJ
Am J Med; 1991 Mar; 90(3):360-6. PubMed ID: 2003518
[TBL] [Abstract][Full Text] [Related]
3. Thyrotropin versus thyroid hormone in regulating bone density and turnover in premenopausal women.
Baqi L; Payer J; Killinger Z; Hruzikova P; Cierny D; Susienkova K; Langer P
Endocr Regul; 2010 Apr; 44(2):57-63. PubMed ID: 20429634
[TBL] [Abstract][Full Text] [Related]
4. Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women.
Paul TL; Kerrigan J; Kelly AM; Braverman LE; Baran DT
JAMA; 1988 Jun; 259(21):3137-41. PubMed ID: 3367489
[TBL] [Abstract][Full Text] [Related]
5. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women.
Ongphiphadhanakul B; Puavilai G; Rajatanavin R
J Med Assoc Thai; 1996 Sep; 79(9):563-7. PubMed ID: 8996984
[TBL] [Abstract][Full Text] [Related]
6. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
[TBL] [Abstract][Full Text] [Related]
7. Low trabecular bone score in postmenopausal women with differentiated thyroid carcinoma after long-term TSH suppressive therapy.
De Mingo Dominguez ML; Guadalix Iglesias S; Martin-Arriscado Arroba C; López Alvarez B; Martínez Diaz-Guerra G; Martinez-Pueyo JI; Ferrero Herrero E; Hawkins Carranza F
Endocrine; 2018 Oct; 62(1):166-173. PubMed ID: 30014437
[TBL] [Abstract][Full Text] [Related]
8. The level of TSH appeared favourable in maintaining bone mineral density in postmenopausal women.
Baqi L; Payer J; Killinger Z; Susienkova K; Jackuliak P; Cierny D; Langer P
Endocr Regul; 2010 Jan; 44(1):9-15. PubMed ID: 20151763
[TBL] [Abstract][Full Text] [Related]
9. The benefit of hormone replacement therapy on bone mass is greater at the vertebral body than posterior processes or proximal femur.
Duan Y; Tabensky A; DeLuca V; Seeman E
Bone; 1997 Nov; 21(5):447-51. PubMed ID: 9356739
[TBL] [Abstract][Full Text] [Related]
10. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine.
Marcocci C; Golia F; Vignali E; Pinchera A
J Bone Miner Res; 1997 Jan; 12(1):72-7. PubMed ID: 9240728
[TBL] [Abstract][Full Text] [Related]
11. Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma.
Reverter JL; Holgado S; Alonso N; Salinas I; Granada ML; Sanmartí A
Endocr Relat Cancer; 2005 Dec; 12(4):973-81. PubMed ID: 16322336
[TBL] [Abstract][Full Text] [Related]
12. A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma.
Diamond T; Nery L; Hales I
J Clin Endocrinol Metab; 1991 Jun; 72(6):1184-8. PubMed ID: 2026740
[TBL] [Abstract][Full Text] [Related]
13. Spinal bone mass after long-term treatment with L-thyroxine in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditis.
Hawkins F; Rigopoulou D; Papapietro K; Lopez MB
Calcif Tissue Int; 1994 Jan; 54(1):16-9. PubMed ID: 8118747
[TBL] [Abstract][Full Text] [Related]
14. High-normal free thyroxine levels are associated with low trabecular bone scores in euthyroid postmenopausal women.
Hwangbo Y; Kim JH; Kim SW; Park YJ; Park DJ; Kim SY; Shin CS; Cho NH
Osteoporos Int; 2016 Feb; 27(2):457-62. PubMed ID: 26252978
[TBL] [Abstract][Full Text] [Related]
15. Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone.
Sijanovic S; Karner I
Medscape Womens Health; 2001 Oct; 6(5):3. PubMed ID: 11698925
[TBL] [Abstract][Full Text] [Related]
16. Long-term thyroxine treatment and bone mineral density.
Franklyn JA; Betteridge J; Daykin J; Holder R; Oates GD; Parle JV; Lilley J; Heath DA; Sheppard MC
Lancet; 1992 Jul; 340(8810):9-13. PubMed ID: 1351654
[TBL] [Abstract][Full Text] [Related]
17. Effect of estrogen replacement therapy upon bone mineral density in thyroxine-treated postmenopausal women with a past history of thyrotoxicosis.
Franklyn JA; Betteridge J; Holder R; Sheppard MC
Thyroid; 1995 Oct; 5(5):359-63. PubMed ID: 8563472
[TBL] [Abstract][Full Text] [Related]
18. A slightly suppressive dose of L-thyroxine does not affect bone turnover and bone mineral density in pre- and postmenopausal women with nontoxic goitre.
De Rosa G; Testa A; Maussier ML; Callà C; Astazi P; Albanese C
Horm Metab Res; 1995 Nov; 27(11):503-7. PubMed ID: 8770627
[TBL] [Abstract][Full Text] [Related]
19. Volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in women with differentiated thyroid cancer under TSH suppression.
Tournis S; Antoniou JD; Liakou CG; Christodoulou J; Papakitsou E; Galanos A; Makris K; Marketos H; Nikopoulou S; Tzavara I; Triantafyllopoulos IK; Dontas I; Papaioannou N; Lyritis GP; Alevizaki M
Clin Endocrinol (Oxf); 2015 Feb; 82(2):197-204. PubMed ID: 25040693
[TBL] [Abstract][Full Text] [Related]
20. Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma.
Görres G; Kaim A; Otte A; Götze M; Müller-Brand J
Eur J Nucl Med; 1996 Jun; 23(6):690-2. PubMed ID: 8662104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]